Attorney Docket No.
Customer No. 03000
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT EXAMINING OPERATION

Applicant	:	Nobuto Yamamoto
Serial No.	:	Continuation Application of ASN 08/618,485, filed March 19, 1996
Filed	:	April 5, 2001
For	:	PREPARATION OF POTENT MACROPHAGE ACTIVATING FACTORS DERIVED FROM CLONED VITAMIN D BINDING PROTEIN AND ITS DOMAIN AND THEIR THERAPEUTIC USAGE FOR CANCER, HIV-INFECTION AND OSTEOPETROSIS
Group	:	
Examiner	:	

PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, DC 20231

Sir:

This application is being filed under 35 C.F.R. 1.53(b). THIS IS NOT A CPA NOR AN RCE, WE REQUEST THAT A NEW APPLICATION SERIAL NUMBER, PLEASE DO NOT ABANDON THE PARENT APPLICATION.

IN THE SPECIFICATION

Please delete lines 25-27 on page 1.

Please amend the specification by inserting the following on page 1 in place thereof:

--This application is a Continuation Application of ASN 08/618,485, filed on March 19, 1996 entitled PREPARATION OF POTENT MACROPHAGE ACTIVATING FACTORS DERIVED FROM CLONED VITAMIN D BINDING PROTEIN AND ITS DOMAIN AND THEIR THERAPEUTIC USAGE FOR CANCER, HIV-INFECTION AND OSTEOPETROSIS which is a continuation-in-part of ASN 08/478,121 filed June 7, 1995, entitled DIAGNOSTIC PROGNOSTIC INDICES FOR CANCER AND AIDS, and the entire disclosures of which are incorporated by reference herein–.

IN THE CLAIMS

Prior to calculating the filing fee, please cancel claims 1-4.

Please add the following claims.

--1. A process for cloning vitamin D_3-binding protein (Gc protein) into baculovirus comprising the step of selecting and using a baculovirus non-fusion vector and a host to clone the vitamin D_3-binding protein Gc protein (Gc protein), wherein the Gc protein has a molecular weight of approximately 52,000, approximately 458 amino acids and 3 distinct domains,

by using cDNA containing initiation codon (-16 Met) through the leader sequence to the +1 amino acid (leu of native Gc protein and introducing the cDNA

to the non-fusion vector with a polylinker carrying the EcoRI site,

isolating a full-length Gc cDNA with EcoRI termini,

digesting the cDNA for Gc protein with EcoRI enzyme, and

ligating with a ligase to produce a construct to express the Gcprotein.

2. A process for producing a cloned macrophage activating factor (GcMAFc) comprising contacting cloned Gc protein a molecular weight of approximately 52,000, approximately 458 amino acids and 3 distinct domains in vitro with immobilized beta-galactosidase and sialidase and obtaining the cloned macrophage activating factor (GcMAFc).

3. A process for producing a cloned macrophage activating factor (GcMAFc) made in accordance with the process of claim 1 comprising contacting cloned Gc protein in vitro with immobilized beta-galactosidase and sialidase and obtaining the cloned macrophage activating factor (GcMAFc).--

The Commissioner of Patents is hereby authorized to charge any fees which may be required, and to credit any overpayment to Account No. 03-0075. A duplicate copy of this sheet is enclosed.

Enclosed is a copy of the prior application, including the Declaration as originally filed.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOW, LTD.

April 5, 2001

By_____

Robert S. Silver
12th Floor, Seven Penn Center
1635 Market Street
Philadelphia, PA 19103-2212
(215) 567-2010
Attorney for Applicant